miRagen Therapeutics (MGEN) PT Lowered to $1 at Wedbush, After Drug Trial Results Published
Tweet
Share
E-mailGet Alerts MGEN Hot Sheet
Price: $23.01 --0%
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush analyst Liana Moussatos lowered the price target on miRagen Therapeutics (NASDAQ: MGEN) to $1.00 (from $6.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Diversified Royalty Corp (DIV:CN) (BEVFF) PT Lowered to Cdn$4.75 at Desjardins
- Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Liana MoussatosSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
